PHARMACYTE BIOTECH, INC. Stock Repurchase Program, Authorized Amount
PHARMACYTE BIOTECH, INC. (PMCB) had Stock Repurchase Program, Authorized Amount of $26.72 million as of 2023-05-11, per its 10-Q filed 2024-03-18.
Discontinued › Notes › Equity
us-gaap:StockRepurchaseProgramAuthorizedAmount1 · last filed 2024-03-18
- 2023-05-11: Stock Repurchase Program, Authorized Amount $26.72M; Stock Repurchase Program, Authorized Amount as first filed $26.46M.
- 2022-05-31: Stock Repurchase Program, Authorized Amount $10.00M.
- 2022-05-22: Stock Repurchase Program, Authorized Amount $10.00M.
| Period end | Stock Repurchase Program, Authorized Amount | Stock Repurchase Program, Authorized Amount as first filed |
|---|---|---|
| 2023-05-11 | $26.72M 10-Q · filed 2024-03-18 | $26.46M 10-Q · filed 2023-09-18 |
| 2022-05-31 | $10.00M 10-Q · filed 2024-03-18 | |
| 2022-05-22 | $10.00M 10-Q · filed 2023-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |